The overall goals are to: Determine COVID-19 vaccine effectiveness in pregnant women for preventing laboratory-confirmed COVID-19 and hospitalization for COVID-19 using real-world clinical data; Determine effectiveness of maternal COVID-19 vaccination dur...
Funder: National Institute of Allergy and Infectious Diseases
Investigator: Zerbo, Ousseny
|
The Study of Transition, Outcomes and Gender (STRONG) is an ongoing cohort study of transgender people enrolled in Kaiser Permanente (KP) integrated health care plans in Georgia (KPGA), Northern California (KPNC) and Southern California (KPSC), and includ...
Funder: National Institute on Aging
Investigator: Silverberg, Michael
|
We are studying the genomes of SARS-CoV-2 in persons with COVID-19 with and without vaccination to identify and describe variants circulating within our patients, including variants of concern (such as Delta or Omicron. We also are assessing which shared ...
Funder: The Rockefeller Foundation
Investigator: Skarbinski, Jacek
|
The goals of this study are to identify primary care settings that serve non-U.S.born persons at risk for latent tuberculosis infection and tuberculosis disease; collect retrospective and prospective electronic medical record data; design and implement cl...
Funder: Centers for Disease Control and Prevention
Investigator: Skarbinski, Jacek
|
The goal of this K01 Career Development Award is to receive mentored training on the development of risk prediction models for dementia in people with HIV using electronic health records data.
The project will quantify the contribution of HIV- and non-HIV...
Funder: National Institute of Allergy and Infectious Diseases
Investigator: Lam, Jennifer
|
This study will identify primary care systems and settings that serve non-U.S.-born persons at risk for latent tuberculosis infection (LTBI) and tuberculosis disease; collect retrospective and prospective electronic medical record data; design and impleme...
Funder: Centers for Disease Control and Prevention
Investigator: Skarbinski, Jacek
|
In partnership with the California Emerging Infection Program and the California Department of Public Health, Kaiser Permanente Northern California will contribute to statewide whole genome sequencing efforts for surveillance for SARS-CoV-2 variants of co...
Funder: Centers for Disease Control and Prevention
Investigator: Skarbinski, Jacek
|
The goal of this study is to use electronic medical records from 2016 to 2020 to evaluate the protective effect of MenB-4C vaccine against gonococcal infections among 16- to 23-year-old persons.
Funder: Centers for Disease Control and Prevention
Investigator: Zerbo, Ousseny
|
This study will evaluate the safety, tolerability, and efficacy of a booster dose of BNT162b2 when administered to study participants who previously received 2 doses of BNT162b2 at least 6 months prior to randomization.
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This phase I open-label dose-finding study will evaluate the safety, tolerability, and immunogenicity of a Sars-Cov-2 RNA vaccine candidate against COVID-19 in healthy 12-year-old children.
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This study will evaluate extended 2-dose regimens in boys and girls ages 10 to 15 who previously received 1 dose of 9vHPV vaccine and did not complete the series and in HPV vaccine-naive boys and girls ages 9 to 14. Both groups will be compared with young...
Funder: Merck ＆ Company, Inc.
Investigator: Klein, Nicola
|
This prospective, observational cohort study, an extension of clinical trial V503-069, will enroll and administer a second dose of 9vHPV to approximately 200 children/teens ages 10 to 15 who received their first 9vHPV vaccine at least 1 year prior. These ...
Funder: Merck ＆ Company, Inc.
Investigator: Klein, Nicola
|
Cancer is the leading cause of death among persons with HIV (PWH). Studies have found significant disparities in cancer therapy initiation and survival for PWH compared with the general population. This study will evaluate differences in cancer treatment ...
Funder: National Cancer Institute
Investigator: Silverberg, Michael
|
This study will evaluate extended 2-dose regimens in 2 different populations: (1) boys and girls 10 to 15 years of age who previously received 1 dose of 9vHPV vaccine and did not complete the series and (2) HPV vaccine-naive boys and girls 9 to 14 years o...
Funder: Merck ＆ Company, Inc.
Investigator: Klein, Nicola
|
To demonstrate that the immune responses induced by BNT162b2 are consistent across the 3 U.S. lots (Lots 1, 2, and 3) in participants without evidence of SARS-CoV-2 infection during the study.
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This work will support and contribute to the COVID-19 vaccine safety work of the VSD: managing site contributions, and participating on working groups and attending conference calls; providing high-quality electronic data for COVID-19 vaccine safety acti...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
Study will perform sequencing on 300 specimens from a mixture of Flublok Quadrivalent vaccine recipients, SD-IIV4 recipients, and unvaccinated individuals; and describe the molecular epidemiology of approximately 300 influenza strains causing disease in v...
Funder: Sanofi Pasteur S.A.
Investigator: Klein, Nicola
|
We will develop a protocol, coordinate, and lead Rapid Cycle Analysis (RCA) activities in order to monitor the safety of COVID-19 vaccines in near real-time and investigate possible associations between the COVID-19 vaccines and a pre-specified list of ad...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
This study is part of the Phase 3 pediatric clinical development program to evaluate the 20-Valent Pneumococcal Conjugate Vaccine for use in infants and children. This clinical trial will provide key safety and pivotal comparative immunogenicity data in i...
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This clinical trial will evaluate treatment with IV administered remdesivir in an outpatient setting in patients with COVID-19 who are at risk for disease progression.
Funder: Gilead Sciences, Inc.
Investigator: Skarbinski, Jacek
|
This study will assess the sero-prevalence and sero-incidence of SARS-CoV-2 infection in Kaiser Permanente Northern California and assess correlates of exposure and immunity among KPNC members.
Funder: National Cancer Institute
Investigator: Skarbinski, Jacek
|
To describe the safety and tolerability profiles of prophylactic BNT162 vaccines in healthy adults after 1 or 2 doses
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This study will estimate influenza vaccine effectiveness by vaccine type and for different ages by combining data from medical records, vaccine registries, and results of clinician-ordered molecular tests for influenza virus infection at Kaiser Permanente...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
People with HIV are at increased risk for dementia due to the combined effects of HIV-associated inflammation and traditional (non-HIV) risk factors such as chronic drug use and cerebrovascular disease. With the widespread use of antiretroviral therapy fo...
Funder: Northern California Community Benefit Programs
Investigator: Lam, Jennifer
|
The risk of acute thrombotic events such as venous thromboembolism (VTE) and ischemic stroke in transgender women receiving hormone therapy was addressed in our longitudinal Study of Transition, Outcomes & Gender (STRONG), supported by the Patient-Centere...
Funder: Patient-Centered Outcomes Research Institute
Investigator: Silverberg, Michael
|
|
